Sohag University
Sohag, Egypt
NCT Number: NCT04790435
Cirrhosis is a condition characterized by diffuse fibrosis, severe disruption of the intrahepatic arterial and venous flow, portal hypertension and, ultimately, liver cell failure. Traditionally, cirrhosis has been dichotomised in compensated and decompensated, and the transition to decompensated cirrhosis happens when any of the following hallmarks occurs: presence of ascites, variceal haemorrhage and/ or hepatic encephalopathy (HE) . In Egypt, HCV is the main cause of liver cirrhosis followed by HBV
Looking for future studies?
Notify Me18 year–65 year
All sexes
Observational
Sohag, Egypt
Cirrhosis is a condition characterized by diffuse fibrosis, severe disruption of the intrahepatic arterial and venous flow, portal hypertension and, ultimately, liver cell failure. Traditionally, cirrhosis has been dichotomised in compensated and decompensated, and the transition to decompensated cirrhosis happens when any of the following hallmarks occurs: presence of ascites, variceal haemorrhage and/ or hepatic encephalopathy (HE). In Egypt, HCV is the main cause of liver cirrhosis followed by HBV. Once cirrhosis transitions from the compensated to the decompensated stage, it is associated with short-term survival (3-5 years) . The concept of acute-on-chronic liver failure (ACLF) has been widely used to study patients who underwent artificial support therapies as a bridge to liver transplantation (LT). In 2009, the Asian Pacific Association for the Study of the Liver (APASL) provided the first consensus on ACLF, defined as "an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy". In 2014, the definition was further expanded to include 'high 28-day mortality'. Therefore, acute on top of chronic liver failure (ACLF) is defined as a syndrome characterized by acute decompensated cirrhosis associated with failure of various organs and high short term mortality rate; based on CANONIC study which is a large scale prospective study, in which the kidneys were the most common affected organs, followed by liver, coagulation, the brain, circulation and the lungs. ACLF can occur in patients with chronic liver disease without cirrhosis (type A), with compensated cirrhosis (type B), and with decompensated cirrhosis (type C) .In many cases, a precipitating factor linked to the development of ACLF can be identified including alcohol intake, reactivation of HBV or acute hepatitis due to HAV or HEV, bacterial infection or GI hemorrhage. The CLIF-C OF score which consists of numbers and types of organ failures (OFs) including kidneys, liver, coagulation, the brain, circulation, and the lungs is associated with 28-day and 90-day mortality. Moreover, some specific organ dysfunction such as kidney dysfunction and moderate HE, when associated with single OF, was also associated with bad prognosis . On this background, diagnostic criteria of ACLF were established according to the presence, type and number of OFs.
The severity of ACLF was graded into different stages according to the number of OFs on ACLF grade 1, grade 2 and grade 3 and mortality correlates with ACLF severity.
To predict prognosis and mortality more accurately. developed CLIF-C-ACLF score which has a greater prognostic capability than CLIF-C- OF, It consists of the CLIF-C- OF combined with age and WBCs count. Few studies have addressed the patterns of acute on chronic liver failure in Egyptian cirrhotic patients . Therefore, we will conduct our study to shed
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 4 weeks from start point.
It will be determined by univariate and multivariate analysis.
Time frame: 4 weeks from start point.
Alcohol intake, reactivation of HBV, acute hepatitis, bacterial infection, and GI haemorrhage
Time frame: 4 weeks from start point
Kidneys, liver, coagulation, the brain, circulation, and the lungs.
Sohag University
Other
Acute-On-Chronic Liver Failure In Cirrhotic Patients In Sohag University Hospital
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05237583
Behavior, Cirrhosis, Liver
Montreal, Quebec, Canada
View Trial DetailsNCT04620538
Adenocarcinoma, Carcinoma
London, United Kingdom
View Trial DetailsNCT05059795
Acute on Chronic Liver Failure, Acute-On-Chronic Liver Failure
Chandigarh, India
View Trial DetailsNCT05339269
Cirrhosis, Liver, Digestive System Diseases
Yangzhou, Jiangsu, China
View Trial Details